Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL28355365 | 0.98 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Methacrylic Acid SCHEMBL11039069 | 0.98 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Methacrylic Acid SCHEMBL11036589 | 0.98 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Methacrylic Acid SCHEMBL5188133 | 0.98 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Methacrylic Acid SCHEMBL6541997 | 0.98 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Methacrylic Acid SCHEMBL25389673 | 0.98 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Methacrylic Acid SCHEMBL11037032 | 0.98 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Methacrylic Acid SCHEMBL3798546 | 0.98 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Methacrylic Acid SCHEMBL14661239 | 0.98 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4HCAR2 | |
| Methacrylic Acid SCHEMBL11039071 | 0.98 | TSHR (0.68) | TSHRHPGDALDH1A1CYP3A4HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 722 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3266908-B1 | ANTI-BACTERIAL METALLO IONOMER POLYMER NANOCOMPOSITE FILAMENTS AND METHODS OF MAKING THE SAME | XEROX CORP (US) | 2020-05-06 | — | — | EP | claimed |
| US-10570290-B2 | Anti-bacterial aqueous ink compositions comprising metal ion composite ionomer resins | XEROX CORPORATION (US) | 2020-02-25 | — | — | US | claimed |
| EP-3266613-B1 | ANTI-BACTERIAL METALLO IONOMER POLYMER COMPOSITE POWDERS AND METHODS OF MAKING THE SAME | XEROX CORP (US) | 2019-10-16 | — | — | EP | claimed |
| US-10405540-B2 | Anti-bacterial metallo ionomer polymer nanocomposite filaments and methods of making the same | XEROX CORPORATION (US) | 2019-09-10 | — | — | US | claimed |
| US-10113059-B2 | Anti-bacterial metallo ionomer polymer nanocomposite powders and methods of making the same | XEROX CORPORATION (US) | 2018-10-30 | — | — | US | claimed |
| US-10095140-B2 | Styrene/acrylate and polyester resin particles | XEROX CORPORATION (US) | 2018-10-09 | — | — | US | claimed |
| US-10067434-B2 | Emulsion aggregation toners | XEROX CORPORATION (US) | 2018-09-04 | — | — | US | claimed |
| US-10018931-B2 | Toner compositions with optimized beta-carboxyethyl acrylate shell latex for improved particle formation and morphology | XEROX CORPORATION (US) | 2018-07-10 | — | — | US | claimed |
| US-10007200-B2 | Antimicrobial toner | XEROX CORPORATION (US) | 2018-06-26 | — | — | US | claimed |
| US-9989873-B1 | Toner compositions with antiplasticizers comprising purine derivative | XEROX CORPORATION (US) | 2018-06-05 | — | — | US | claimed |
| EP-0928991-A2 | Toner preparation processes | Xerox Corporation (US) | 1999-07-14 | — | — | EP | claimed |
| US-5869215-A | Toner compositions and processes thereof | XEROX CORPORATION (US) | 1999-02-09 | — | — | US | claimed |
| US-5863698-A | MIXING COLORANT COMPRISING PHOSPHATE-CONTAINING SURFACTANT, LATEX EMULSION, HEATING, STABILIZING | XEROX CORPORATION (US) | 1999-01-26 | — | — | US | claimed |
| US-5858601-A | Toner processes | XEROX CORPORATION (US) | 1999-01-12 | — | — | US | claimed |
| US-5766818-A | Toner processes with hydrolyzable surfactant | XEROX CORPORATION (US) | 1998-06-16 | — | — | US | claimed |
| US-5766817-A | AGGREGATING COLORANT DISPERSION WITH LATEX MINIEMULSION CONTAINING POLYMER AND IONIC AND NONIONIC SURFACTANTS, COALESCING THE AGGREGATES GENERATED | XEROX CORPORATION (US) | 1998-06-16 | — | — | US | claimed |
| US-5763133-A | Toner compositions and processes | XEROX CORPORATION (US) | 1998-06-09 | — | — | US | claimed |
| US-5747215-A | Toner compositions and processes | XEROX CORPORATION (US) | 1998-05-05 | — | — | US | claimed |
| EP-0116611-A1 | PROSTHESES CONTACT LENSES AND POLYMERS THEREFOR | CONTACT LENSES (MANUFACTURING) LIMITED (GB) | 1984-08-29 | — | — | EP | claimed |
| WO-1984000968-A1 | PROSTHESES CONTACT LENSES AND POLYMERS THEREFOR | CONTACT LENS MFG LTD (GB) | 1984-03-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10113059-B2 | Anti-bacterial metallo ionomer polymer nanocomposite powders and methods of making the same | RPN1, RPN2, MSH2 | TSHR 4205/4885HPGD 1695/4885ALDH1A1 2365/4885 |
| US-10405540-B2 | Anti-bacterial metallo ionomer polymer nanocomposite filaments and methods of making the same | TERB1, NBAS, MFAP1 | TSHR 4098/4885HPGD 2095/4885ALDH1A1 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.